Nonmyeloablative stem cell transplantation for the treatment of cancer and life-threatening nonmalignant disorders: Past accomplishments and future goals

Cancer Chemotherapy and Pharmacology

Volumn 48, Issue SUPPL. 1, 2001, Pages

  Slavin, Shimon ^a   Or, Reuven ^a   Aker, Memet ^a   Shapira, Michael Y ^a   Panigrahi, Soumya ^a   Symeonidis, Argiris ^a   Cividalli, Gabriel ^a   Nagler, Arnon ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Allogeneic cell therapy; Blood stem cell transplantation; Bone marrow transplantation; Donor lymphocyte infusion; Hematologic malignancies; Minitransplant; Nonmalignant hematologic diseases; Nonmyeloablative stem cell transplantation

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ANIMAL; BONE MARROW TRANSPLANTATION; FORECASTING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; METHODOLOGY; NEOPLASM; REVIEW;

ANIMALS; BONE MARROW TRANSPLANTATION; FORECASTING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS;

EID: 0001904572     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800100311     Document Type: Article

References (24)

1. Carella AM, Champlin R, Slavin S, McSweeney P, Strob R (2000) "Mini-allografts": ongoing trials in humans. Bone Marrow Transplant 25:345
2. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343:750
3. Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gächter A, Knapp R, Böck G, Gassner C, Schiller L, Petersen F, Niederwieser D (1996) Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 88:1501
4. Giralt S, Estey E, Albitar M, Van Besien K, Rondon G, Anderlini PS, Khouri I, Gajewski J, Mehma R, Claxton D, Andersson B, Beran M. Przepiorka D, Koller C, Kornblau S, Körbling M, Keating M, Kautarziah H, Champlin R (1997) Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89:4531
5. Horowitz M, Gale RP, Sondel PM, Goldman JM, Karsay J, Kolb HJ, Rimma A, Ringden O, Rozman C, Speck B (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555
6. Kapelushnik J, Or R, Aker M, Cividalli G, Nagler A, Naparstek E, Varadi G, Ackerstein A, Amar A, Slavin S (1996) Allogeneic cell therapy of severe beta thalassemia major by displacement of host stem cells in mixed chimera by donor blood lymphocytes. Bone Marrow Transplant 19:96
7. Kapelushnik J, Or R, Slavin S, Nagler A (1997) Fludarabine based protocol for BMT in Fanconi anemia. Bone Marrow Transplant 29:1109
8. Khouri I, Keating M, Przepiorka D, O'Brien S, Giralt S, Körbling M, Champlin R (1996) Engraftment and induction of GVL with fludarabine based non-ablative preparative regimens in patients with chronic lymphocytic leukemia and lymphoma. Blood 88 [Suppl 1]:301a
9. McSweeney PA, Wagner JL, Maloney DG, Radich J, Shizuru J, Bensinger WI, Bryant E, Chauncey TR, Flowers MED, Kauffman M, Minor CS, Nash RA, Blume K, Storb R (1998) Outpatient PBSC allografts using immunosuppression with low-dose TBI before, and cyclosporine (CSP) and mycophenolate mofetil (MMF) after transplant. Blood 92 [Suppl 1]:519a
10. Moscovitch M, Slavin S (1984) Anti-tumor effects of allogeneic bone marrow transplantation in (NZBxNZW)F1 hybrids with spontaneous lymphosarcoma. J Immunol 132:997
11. Naparstek E, Nagler A, Or R, Slavin S (1996) Allogeneic cell mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic BMT for hematological malignancies. In: Ceka JM, Tarasaki PI (eds) Clinical transplantation. Tissue Typing Laboratory, Los Angeles, p 281
12. Ringden O, Horowitz MM, for the Advisory Committee of the International BMT Registry (1989) Graft-versus-leukemia reactions in humans. Transplant Proc 21:2989
13. Slavin S (1987) Total lymphoid irradiation. Immunol Today 3:88
14. Slavin S (2000) Cancer immunotherapy with alloreactive lymphocytes. N Engl J Med 343:802
15. Slavin S, Strober S, Fuks Z, Kaplan HS (1976) Long-term survival of skin allografts in mice treated with fractionated total lymphoid irradiation. Science 193:1252
16. Slavin S, Fuks Z, Kaplan HS, Strober S (1978) Transplantation of allogeneic bone marrow without graft vs host disease using total lymphoid irradiation. J Exp Med 147:963
17. Slavin S, Weiss L, Morecki S, Weigensberg M (1981) Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol Immunother 11:155
18. Slavin S, Or R, Naparstek E, Ackerstein A, Weiss L (1988) Cellular-mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man. Blood 72 [Suppl 1]:407a
19. Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik Y, Or R (1995) Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 23:1553
20. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, Brautbar C, Or R (1996) Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation. Blood 87:2195
21. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Ben-Tal O, Eldor A, Or R (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood 91:756
22. Slavin S, Nagler A, Naparstek E, Varadi G, Ben-Yosef R, Panighari S, Samuel S, Ackerstein A, Or R (1999) A new non-myeloablative protocol using fludarabine and low-dose TBI in preparation for allogeneic blood stem cell transplantation for high risk patients with malignant and non-malignant disorders. Blood 94:10 [Suppl 1]:388b
23. Slavin S, Nagler A, Varadi G, Or R (2000) Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leuke-mia and severe systemic psoriasis and psoriatic polyarthritis. Exp Hematol 28:853
24. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, Buckner CD, Anasetti C, Appelbaum FR, Badger C (1989) Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73:1720